OncoMatch/Breast Cancer/ESR1 (ER)
Breast CancerESR1 (ER) Clinical Trials
Estrogen receptor (ER) expression defines hormone receptor-positive breast cancer — approximately 75% of cases — and determines eligibility for endocrine therapy. Acquired ESR1 mutations arise in metastatic ER+ disease after aromatase inhibitor exposure and confer resistance. Trials test selective estrogen receptor degraders (SERDs) including elacestrant (FDA-approved for ESR1-mutant disease), CDK4/6 inhibitor combinations, and novel ESR1-targeting agents.
Top recruiting ESR1 (ER) Breast Cancer trials
Ranked by phase and US site count. See all 260 trials matched to your profile →
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Novartis Pharmaceuticals
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Browse other molecular targets with active Breast Cancer trials.